Oramed Other Stockholder Equity vs Total Current Liabilities Analysis

ORMP Stock

USD 2.37 0.10 4.05%

Oramed Pharmaceuticals financial indicator trend analysis is much more than just breaking down Oramed Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oramed Pharmaceuticals is a good investment. Please check the relationship between Oramed Pharmaceuticals Other Stockholder Equity and its Total Current Liabilities accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.

Other Stockholder Equity vs Total Current Liabilities

Other Stockholder Equity vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oramed Pharmaceuticals Other Stockholder Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Oramed Pharmaceuticals' Other Stockholder Equity and Total Current Liabilities is 0.84. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Oramed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Oramed Pharmaceuticals' Other Stockholder Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Oramed Pharmaceuticals are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Other Stockholder Equity i.e., Oramed Pharmaceuticals' Other Stockholder Equity and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Other Stockholder Equity

Total Current Liabilities

Total Current Liabilities is an item on Oramed Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Oramed Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Oramed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oramed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.At this time, Oramed Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 05/15/2024, Enterprise Value is likely to grow to about 405.9 M, while Tax Provision is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Interest Income	3.6M	4.6M	5.3M	5.6M
Net Interest Income	3.6M	4.6M	5.3M	5.6M

Interest Income Net Interest Income

Oramed Pharmaceuticals fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Net Debt	Accounts Payable	Cash	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Current Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Property Plant And Equipment Gross	Short Term Debt	Short Term Investments	Net Receivables	Other Liab
Other Current Liab		0.87	0.77	-0.85	0.65	0.65	0.83	0.57	0.83	0.8	-0.56	0.66	0.63	0.79	0.44	0.81	0.79	0.72	0.76	0.3	0.09	0.52	0.35	0.76	-0.09	0.42
Total Current Liabilities	0.87		0.77	-0.91	0.67	0.61	0.84	0.76	0.88	0.82	-0.7	0.85	0.74	0.77	0.61	0.83	0.77	0.65	0.69	0.55	0.34	0.42	0.27	0.68	0.03	0.56
Total Stockholder Equity	0.77	0.77		-0.91	0.82	0.82	0.99	0.23	0.96	1.0	-0.78	0.91	0.86	0.99	0.05	0.9	0.99	0.97	0.98	0.25	0.26	0.77	0.56	0.92	-0.04	0.02
Retained Earnings	-0.85	-0.91	-0.91		-0.76	-0.73	-0.95	-0.51	-0.97	-0.93	0.76	-0.89	-0.81	-0.92	-0.32	-0.92	-0.92	-0.82	-0.86	-0.33	-0.25	-0.59	-0.46	-0.85	0.02	-0.26
Common Stock Total Equity	0.65	0.67	0.82	-0.76		0.98	0.82	0.22	0.79	0.82	-0.71	0.72	0.77	0.81	0.07	0.79	0.81	0.74	0.81	0.24	0.29	0.92	0.24	0.72	-0.03	0.14
Common Stock Shares Outstanding	0.65	0.61	0.82	-0.73	0.98		0.81	0.15	0.76	0.81	-0.6	0.67	0.68	0.82	0.02	0.77	0.82	0.77	0.83	0.09	0.14	0.96	0.29	0.78	-0.02	0.11
Other Stockholder Equity	0.83	0.84	0.99	-0.95	0.82	0.81		0.33	0.99	0.99	-0.76	0.91	0.84	0.99	0.16	0.93	0.99	0.94	0.97	0.25	0.22	0.73	0.52	0.93	-0.05	0.12
Total Liab	0.57	0.76	0.23	-0.51	0.22	0.15	0.33		0.39	0.32	-0.24	0.42	0.22	0.25	0.97	0.34	0.25	0.1	0.13	0.57	0.13	-0.06	-0.03	0.23	0.12	0.91
Common Stock	0.83	0.88	0.96	-0.97	0.79	0.76	0.99	0.39		0.98	-0.8	0.92	0.87	0.96	0.21	0.93	0.96	0.89	0.92	0.33	0.29	0.65	0.46	0.88	-0.07	0.16
Total Assets	0.8	0.82	1.0	-0.93	0.82	0.81	0.99	0.32	0.98		-0.78	0.92	0.86	0.99	0.15	0.91	0.99	0.95	0.97	0.3	0.27	0.74	0.54	0.92	-0.03	0.12
Net Debt	-0.56	-0.7	-0.78	0.76	-0.71	-0.6	-0.76	-0.24	-0.8	-0.78		-0.8	-0.98	-0.73	-0.03	-0.75	-0.73	-0.7	-0.71	-0.6	-0.77	-0.56	-0.45	-0.5	0.02	0.03
Accounts Payable	0.66	0.85	0.91	-0.89	0.72	0.67	0.91	0.42	0.92	0.92	-0.8		0.85	0.89	0.24	0.85	0.89	0.81	0.83	0.46	0.43	0.57	0.4	0.79	0.04	0.19
Cash	0.63	0.74	0.86	-0.81	0.77	0.68	0.84	0.22	0.87	0.86	-0.98	0.85		0.82	0.02	0.81	0.82	0.8	0.8	0.54	0.69	0.64	0.48	0.61	-0.04	-0.02
Cash And Short Term Investments	0.79	0.77	0.99	-0.92	0.81	0.82	0.99	0.25	0.96	0.99	-0.73	0.89	0.82		0.08	0.91	1.0	0.97	0.99	0.18	0.17	0.77	0.56	0.96	-0.05	0.06
Non Current Liabilities Total	0.44	0.61	0.05	-0.32	0.07	0.02	0.16	0.97	0.21	0.15	-0.03	0.24	0.02	0.08		0.16	0.08	-0.06	-0.03	0.49	-0.01	-0.19	-0.17	0.1	0.1	0.97
Other Current Assets	0.81	0.83	0.9	-0.92	0.79	0.77	0.93	0.34	0.93	0.91	-0.75	0.85	0.81	0.91	0.16		0.91	0.86	0.89	0.2	0.27	0.68	0.45	0.84	-0.15	0.13
Total Current Assets	0.79	0.77	0.99	-0.92	0.81	0.82	0.99	0.25	0.96	0.99	-0.73	0.89	0.82	1.0	0.08	0.91		0.97	0.99	0.17	0.17	0.77	0.56	0.96	-0.05	0.06
Short Long Term Debt Total	0.72	0.65	0.97	-0.82	0.74	0.77	0.94	0.1	0.89	0.95	-0.7	0.81	0.8	0.97	-0.06	0.86	0.97		0.99	0.11	0.17	0.77	0.7	0.93	-0.02	-0.09
Property Plant And Equipment Net	0.76	0.69	0.98	-0.86	0.81	0.83	0.97	0.13	0.92	0.97	-0.71	0.83	0.8	0.99	-0.03	0.89	0.99	0.99		0.11	0.15	0.82	0.61	0.95	-0.08	-0.04
Non Current Assets Total	0.3	0.55	0.25	-0.33	0.24	0.09	0.25	0.57	0.33	0.3	-0.6	0.46	0.54	0.18	0.49	0.2	0.17	0.11	0.11		0.76	0.0	-0.02	-0.03	0.11	0.45
Non Currrent Assets Other	0.09	0.34	0.26	-0.25	0.29	0.14	0.22	0.13	0.29	0.27	-0.77	0.43	0.69	0.17	-0.01	0.27	0.17	0.17	0.15	0.76		0.13	0.12	-0.12	0.05	-0.05
Property Plant And Equipment Gross	0.52	0.42	0.77	-0.59	0.92	0.96	0.73	-0.06	0.65	0.74	-0.56	0.57	0.64	0.77	-0.19	0.68	0.77	0.77	0.82	0.0	0.13		0.38	0.73	-0.04	-0.08
Short Term Debt	0.35	0.27	0.56	-0.46	0.24	0.29	0.52	-0.03	0.46	0.54	-0.45	0.4	0.48	0.56	-0.17	0.45	0.56	0.7	0.61	-0.02	0.12	0.38		0.53	0.32	-0.26
Short Term Investments	0.76	0.68	0.92	-0.85	0.72	0.78	0.93	0.23	0.88	0.92	-0.5	0.79	0.61	0.96	0.1	0.84	0.96	0.93	0.95	-0.03	-0.12	0.73	0.53		-0.04	0.09
Net Receivables	-0.09	0.03	-0.04	0.02	-0.03	-0.02	-0.05	0.12	-0.07	-0.03	0.02	0.04	-0.04	-0.05	0.1	-0.15	-0.05	-0.02	-0.08	0.11	0.05	-0.04	0.32	-0.04		0.11
Other Liab	0.42	0.56	0.02	-0.26	0.14	0.11	0.12	0.91	0.16	0.12	0.03	0.19	-0.02	0.06	0.97	0.13	0.06	-0.09	-0.04	0.45	-0.05	-0.08	-0.26	0.09	0.11

Click cells to compare fundamentals

Oramed Pharmaceuticals Account Relationship Matchups

Oramed Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	1.2M	1.2M	70.0	2.0M	2.3M	2.4M
Total Current Liabilities	4.5M	6.7M	6.5K	5.7M	6.6M	6.9M
Total Stockholder Equity	32.9M	115.8M	153.8K	151.8M	174.6M	183.3M
Retained Earnings	(92.6M)	(114.9M)	(154.5K)	(163.1M)	(146.8M)	(139.4M)
Common Stock Total Equity	207K	208K	284K	424K	487.6K	512.0K
Common Stock Shares Outstanding	20.5M	28.5M	39.6M	39.0M	44.8M	47.1M
Other Stockholder Equity	125.2M	230.2M	307.9K	314.4M	361.6M	379.7M
Total Liab	11.8M	11.5M	11.3K	10.5M	12.1M	6.1M
Common Stock	284K	424K	470.0	476K	547.4K	574.8K
Total Assets	44.6M	128.0M	4.3K	161.6M	185.9M	195.2M
Net Debt	(19.2M)	(76.7M)	(32.3K)	(39.6M)	(35.6M)	(33.8M)
Accounts Payable	594K	2.6M	4.2K	2.2M	2.5M	2.6M
Cash	19.3M	77.2M	33.2K	40.5M	46.5M	48.9M
Cash And Short Term Investments	39.9M	94.1M	38.4K	155.7M	179.1M	188.0M
Liabilities And Stockholders Equity	44.6M	128.0M	165.1K	161.6M	185.9M	195.2M
Non Current Liabilities Total	7.2M	4.8M	4.8K	4.7M	5.5M	4.0M
Other Current Assets	611K	1.2M	121.7K	1.4M	1.6M	1.7M
Total Current Assets	40.5M	95.3M	160.2K	157.1M	180.7M	189.7M
Property Plant And Equipment Net	174K	932K	1.5K	1.8M	2.1M	2.2M
Non Current Assets Total	4.1M	32.7M	(155.9K)	4.5M	5.2M	6.4M
Property Plant And Equipment Gross	174K	932K	1.8M	1.6M	1.8M	1.9M
Short Term Investments	20.6M	16.9M	5.2K	115.3M	132.5M	139.2M
Other Liab	10.0M	7.2M	4.4M	4.1M	4.7M	6.0M
Property Plant Equipment	24K	99K	930K	1.8M	2.1M	2.2M
Net Tangible Assets	19.4M	32.9M	115.8M	151.8M	174.6M	183.3M
Capital Surpluse	99.4M	100.3M	125.2M	230.2M	264.7M	278.0M
Long Term Investments	3.9M	31.7M	2.7M	54.9M	63.2M	66.3M
Net Invested Capital	32.9M	115.8M	151.8M	214.8M	247.1M	259.4M
Net Working Capital	36.0M	88.7M	151.4M	109.4M	125.8M	71.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Oramed Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Oramed Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Oramed Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Oramed Pharmaceuticals Stock:

How To Invest In Oramed

Details

Is Oramed Stock a good investment?

Details

What is Oramed Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Oramed Stock analysis

When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios

Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.26

Revenue Per Share

0.017

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.05)

Return On Equity

0.0648

The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oramed Other Stockholder Equity vs Total Current Liabilities Analysis

Other Stockholder Equity vs Total Current Liabilities

Other Stockholder Equity vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Other Stockholder Equity

Total Current Liabilities

Oramed Pharmaceuticals fundamental ratios Correlations

Oramed Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oramed Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Oramed Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.99	Total Stockholder Equity
Common Stock	+ 0.99	Other Stockholder Equity

Cash	- 0.98	Net Debt
Common Stock	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Total Assets	- 0.93	Retained Earnings
Total Current Assets	- 0.92	Retained Earnings
Other Current Assets	- 0.92	Retained Earnings